Benzinga | Feb 26, 2021 11:53AM EST

Mizuho Maintains Buy on Sarepta Therapeutics, Raises Price Target to $160

Mizuho analyst Difei Yang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $158 to $160.